肾上腺素与去甲肾上腺素在心脏骤停后复苏后休克患者中的比较
该多中心观察性研究纳入2011-2018年五家医院连续管理的院外心脏骤停后复苏后休克患者766例,其中285例(37%)接受肾上腺素、481例(63%)接受去甲肾上腺素持续静脉升压治疗。主要终点全因住院死亡率在肾上腺素组显著更高(OR 2.6;95%CI 1.4-4.7;P=0.002);心血管住院死亡率(aOR 5.5;95%CI 3.0-10.3;P<0.001)及出院时脑功能分类(CPC)3-5分比例亦更高,敏感性分析结果一致,倾向性评分分析显示相似结果(aOR 2.1;95%CI 1.1-4.0;P=0.02)。作者认为,在更多数据出现前,重症医生可能倾向选择去甲肾上腺素而非肾上腺素治疗院外心脏骤停后复苏后休克。
要点
- 院外心脏骤停后复苏后休克患者中,肾上腺素组全因住院死亡率显著高于去甲肾上腺素组(OR 2.6;95%CI 1.4-4.7;P=0.002)。
- 肾上腺素组心血管住院死亡率亦更高(aOR 5.5;95%CI 3.0-10.3;P<0.001)。
- 肾上腺素组出院时CPC 3-5分(不良神经功能结局)比例更高。
- 倾向性评分分析显示相似结果(aOR 2.1;95%CI 1.1-4.0;P=0.02),敏感性分析结果一致。
- 作者认为,在更多数据出现前,重症医生可能倾向选择去甲肾上腺素而非肾上腺素治疗院外心脏骤停后复苏后休克。
适用人群与场景
- 院外心脏骤停后发生复苏后休克、在2011-2018年间于五家医院管理的连续患者。
处置流程与药物剂量
- 持续静脉升压治疗选用肾上腺素或去甲肾上腺素;肾上腺素组285例(37%),去甲肾上腺素组481例(63%)。
研究设计与关键结果
- 多中心观察性研究,纳入五家医院766例院外心脏骤停后复苏后休克患者,肾上腺素组285例(37%),去甲肾上腺素组481例(63%)。
- 主要终点全因住院死亡率:肾上腺素组显著高于去甲肾上腺素组(OR 2.6;95%CI 1.4-4.7;P=0.002)。
- 次要终点心血管住院死亡率:肾上腺素组更高(aOR 5.5;95%CI 3.0-10.3;P<0.001)。
- 次要终点出院时CPC 3-5分(不良神经功能结局)比例:肾上腺素组更高。
- 倾向性评分分析控制混杂后结果相似(aOR 2.1;95%CI 1.1-4.0;P=0.02);多项敏感性分析结果一致。
证据类型、等级与局限
- 证据类型:多中心观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在更多数据出现前,重症医生可能倾向选择去甲肾上腺素而非肾上腺素治疗院外心脏骤停后复苏后休克。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Whether epinephrine or norepinephrine is preferable as the continuous intravenous vasopressor used to treat post-resuscitation shock is unclear. We assessed outcomes of patients with post-resuscitation shock after out-of-hospital cardiac arrest according to whether the continuous intravenous vasopressor used was epinephrine or norepinephrine.
METHODS: We conducted an observational multicenter study of consecutive patients managed in 2011-2018 for post-resuscitation shock. The primary outcome was all-cause hospital mortality, and secondary outcomes were cardiovascular hospital mortality and unfavorable neurological outcome (Cerebral Performance Category 3-5). A multivariate regression analysis and a propensity score analysis were performed, as well as several sensitivity analyses.
RESULTS: Of the 766 patients included in five hospitals, 285 (37%) received epinephrine and 481 (63%) norepinephrine. All-cause hospital mortality was significantly higher in the epinephrine group (OR 2.6; 95%CI 1.4-4.7; P = 0.002). Cardiovascular hospital mortality was also higher with epinephrine (aOR 5.5; 95%CI 3.0-10.3; P < 0.001), as was the proportion of patients with CPC of 3-5 at hospital discharge. Sensitivity analyses produced consistent results. The analysis involving adjustment on a propensity score to control for confounders showed similar findings (aOR 2.1; 95%CI 1.1-4.0; P = 0.02).
CONCLUSION: Among patients with post-resuscitation shock after out-of-hospital cardiac arrest, use of epinephrine was associated with higher all-cause and cardiovascular-specific mortality, compared with norepinephrine infusion. Until additional data become available, intensivists may want to choose norepinephrine rather than epinephrine for the treatment of post-resuscitation shock after OHCA.
参考来源
- Bougouin W, Slimani K, Renaudier M, et al. Epinephrine versus norepinephrine in cardiac arrest patients with post-resuscitation shock. Intensive Care Med. 2022. PMID: 35129643. doi:10.1007/s00134-021-06608-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。